Stockscreener 앱 받기
27.87
1.87%
-0.53
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Travere Therapeutics : Investor Fact Sheet - marketscreener.com
Rate Hike: Is Travere Therapeutics Inc stock heavily shortedMarket Trend Review & Low Risk Entry Point Guides - baoquankhu1.vn
Chipmakers Recap: Whats the MACD signal for Travere Therapeutics IncMarket Activity Report & Technical Confirmation Alerts - baoquankhu1.vn
Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses - TradingView — Track All Markets
First Week of September 18th Options Trading For Travere Therapeutics (TVTX) - Nasdaq
TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm - FinancialContent
Two Biotechs to Play in Uncertain Times - TheStreet Pro
Travere plummets as FDA extends Filspari review for rare kidney disorder - MSN
Equities Analysts Issue Forecasts for TVTX FY2030 Earnings - MarketBeat
Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential - Seeking Alpha
Why Did TVTX Stock Crash 30% In Pre-Market Today? - Stocktwits
Travere, Ligand hammered on a surprise delay for their linchpin drug - MSN
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Finviz
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Travere Therapeutics (TVTX) and Beyond Air (XAIR) - The Globe and Mail
Is Travere Therapeutics (TVTX) Pricing Reflect Long Term Value After Recent Share Price Pullback - Yahoo Finance
Travere Therapeutics (TVTX) Is Down 18.7% After FDA Extends FILSPARI FSGS Review Timeline – Has The Bull Case Changed? - Yahoo Finance
INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC - GlobeNewswire
(TVTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Travere stock rises as FDA extends Filspari review timeline - Investing.com
Travere stock rises as FDA extends Filspari review timeline By Investing.com - Investing.com UK
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
US FDA extends review of Travere’s drug for rare kidney disease - WHTC
Biggest stock movers Wednesday: INTC, WRD, TVTX, and more (RIVN:NASDAQ) - Seeking Alpha
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS - BioSpace
Travere Therapeutics (TVTX) Suffers Significant Decline - GuruFocus
FDA extends review timeline for Travere’s FSGS drug application By Investing.com - Investing.com Nigeria
Why Travere Therapeutics Stock Got Trounced on Tuesday - Yahoo Finance
TVTX ALERT: Investigation Launched into Travere - GlobeNewswire
TVTX ALERT: Investigation Launched into Travere Therapeutics, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - GlobeNewswire Inc.
Travere Therapeutics provides corporate update and 2026 outlook - MSN
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS - FinancialContent
FDA Extends Review Timeline for Travere’s FILSPARI sNDA - TipRanks
Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug - Investor's Business Daily
Travere Therapeutics FDA Review Extension for FILSPARI - TradingView — Track All Markets
FDA pushes back Travere Therapeutics (NASDAQ: TVTX) FILSPARI FSGS decision date - Stock Titan
Travere shares fall as US FDA extends review of rare kidney disease drug - Reuters
FDA Extends Review of Travere Therapeutics' Filspari sNDA - GuruFocus
Leerink says Travere’s Filspari PDUFA extension removes worst case scenario - TipRanks
SHAREHOLDER ALERT: Travere Therapeutics, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Who Lost Money Should Contact The Firm - GlobeNewswire
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April: Retail Is Divided On Eventual Approval - Stocktwits
Travere Therapeutics (TVTX) Faces FDA Review Delay, Shares Drop 20% - GuruFocus
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13 - TechStock²
Travere Therapeutics stock slides as FDA pushes Filspari FSGS decision into April - TechStock²
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April - Asianet Newsable
Travere Therapeutics Says FDA Extends Review of Filspari to April; Shares Fall - marketscreener.com
Travere Therapeutics Shares Fall After FDA Extends Filspari Review - marketscreener.com
Travere Therapeutics (TVTX) Sees FDA Review Extension for FILSPA - GuruFocus
Travere Therapeutics (TVTX) Sees FDA Review Extension for FILSPARI - GuruFocus
FDA extends review timeline for Travere’s FSGS drug application - Investing.com India
Travere Therapeutics (NASDAQ:TVTX) Shares Gap DownHere's What Happened - MarketBeat
US FDA extends review of Travere's drug for rare kidney disease - marketscreener.com
Travere Therapeutics says FDA extends review of sNDA for Filspari (sparsentan) in FSGS - marketscreener.com
FDA extends review of first potential drug for rare FSGS kidney disease - Stock Titan
Aug Levels: Is Travere Therapeutics Inc. stock a contrarian buyJuly 2025 Fed Impact & Weekly Watchlist for Hot Stocks - Bộ Nội Vụ
Travere Therapeutics Stock (TVTX) Opinions on FDA Data Request - Quiver Quantitative
Travere Therapeutics Becomes Oversold (TVTX) - Nasdaq
Gains Recap: What Wall Street predicts for Travere Therapeutics Inc stock price2025 Market WrapUp & Stepwise Trade Execution Plans - moha.gov.vn
Travere Therapeutics Sees Unusually High Options Volume (NASDAQ:TVTX) - MarketBeat
Options Bears Eye Plummeting Biotech Stock - Schaeffer's Investment Research
4.73%
0.92%
자본화:
|
볼륨(24시간):